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Abstract: The final meeting of the EXPOsOMICS project “Final Policy Workshop and Stakeholder Consultation” took place
28–29 March 2017 to present the main results of the project and discuss their implications both for future research and
for regulatory and policy activities. This paper summarizes presentations and discussions at the meeting related with the
main results and advances in exposome research achieved through the EXPOsOMICS project; on other parallel research
initiatives on the study of the exposome in Europe and in the United States and their complementarity to EXPOsOMICS;
lessons learned from these early studies on the exposome and how they may shape the future of research
on environmental exposure assessment; and finally the broader implications of exposome research for risk
assessment and policy development on environmental exposures. The main results of EXPOsOMICS in relation
to studies of the external exposome and internal exposome in relation to both air pollution and water
contaminants were presented as well as new technologies for environmental health research (adductomics)
and advances in statistical methods. Although exposome research strengthens the scientific basis for policy
development, there is a need in terms of showing added value for public health to: improve communication
of research results to non-scientific audiences; target research to the broader landscape of societal challenges;
and draw applicable conclusions. Priorities for future work include the development and standardization of
methodologies and technologies for assessing the external and internal exposome, improved data sharing
and integration, and the demonstration of the added value of exposome science over conventional
approaches in answering priority policy questions.
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Background and objectives
The final meeting of the EXPOsOMICS project “Final
Policy Workshop and Stakeholder Consultation” took
place in Brussels, Belgium on 28–29 March 2017. The
meeting programme was structured around the main re-
search topics in EXPOsOMICS, and the presentations
fell into four main themes: presentation of the main re-
sults and the advances in exposome research achieved
through the EXPOsOMICS project; presentations on
other parallel research initiatives on the study of the
exposome in Europe and in the United States and their
complementarity to EXPOsOMICS; lessons learned from
these early studies on the exposome and how they may
shape future research on environmental exposure assess-
ment; and finally the broader implications of exposome
research for hazard identification, risk assessment and
policy development on environmental exposures. In
addition, the programme included three plenary sessions
– on the external exposome, the internal exposome and
on policy translation – each of which was led by two
discussants who introduced the themes and promoted
discussion amongst the participants. This paper summa-
rizes the presentations and discussions at this meeting.
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Overview of EXPOsOMICS: Relevance to hazard
identification and risk assessment
There are two broad interpretations of the exposome
concept, or the totality of environmental exposures from
conception onwards, and they are complementary [1–3].
One, called “top-down”, is mainly interested in identify-
ing new causes of disease by an agnostic approach based
on omic technologies. This first approach is sometimes
called “EWAS”, or “exposome-wide association study”,
and utilizes methods such as metabolomics or adduc-
tomics to generate new hypotheses on disease etiology.
The second general approach is called “bottom-up”
and starts with a set of exposures or environmental
compartments to determine the pathways or networks
by which such exposures lead to disease, i.e. which
pathways/networks are perturbed. We have used the
latter approach in the EXPOsOMICS investigation as
we explain below [4].
The context of EXPOsOMICS is the rapidly develop-
ing exposome field, including exposure assessment and
the use of omic technologies. The overall objective of
the EXPOsOMICS project was to comprehensively
integrate both external and internal exposomes at the
individual level and to provide a holistic approach to
exposure science. The scientific questions that were ad-
dressed by EXPOsOMICS are presented in Table 1. The
main results of EXPOsOMICS in relation to studies of
the external and internal exposome are presented below
as well as those for new technologies for environmental
health research (adductomics) and advances in statistical
methods (Table 1). EXPOsOMICS focussed on two high
priority environmental pollutants, air pollution and
water contaminants, exploiting existing short-term and
long-term European population studies, integrating fin-
dings using harmonized external and internal assessment
approaches in studies of critical life stages (conception
Table 1 Summary of research questions and main outputs of the EXPOsOMICS project
Research Question Main Outputs
(1) Is it possible to refine exposure assessment to air pollution and
water contaminants using a combination of personal exposure
monitoring and omic technologies?
-Detailed 24 h PEMs for PM2.5 and UFP conducted on 200 participants
-LUR models for PM2.5 and NO2 developed for Western Europe
-LUR models for UFP and oxidative potential of PM2.5 developed in
six European areas
-Short-term exposure to air pollutants induced changes in omic profiles,
including gene expression, metabolites, and immune markers
-A expanded range of DBPs in air, water and/or in biological samples such
as exhaled breath and urine were measured/modeled
-Numerous metabolic and transcriptional changes due to swimming in a
chlorinated pool
(2) Will that refinement lead to more accurate estimates of the
association with selected diseases, by reducing measurement error?
-Increased RRs for total mortality and ischemic heart disease and asthma
incidence using PM2.5 deattenuation factors from the PEM study
-Positive association between high levels of brominated THM exposure
and colorectal cancer risk
(3) Do new approaches allow the investigation of the effects of
mixtures in addition to single components?
-Lack of overlap between omics signals for different air pollutants
(may suggest the ability of omics to detect pollutant-specific biological
effects)
(4) Do they improve the investigation of dose-response relationships? -Omics signals occurred at very low levels of exposure and following
short-term exposure
(5) Is it possible to strengthen causal reasoning by using the
“meet-in-the-middle” concept, i.e. investigate the temporal sequence
of exposure, biological pathway perturbation and disease onset?
-Metabolomics was used to study meet-in-the-middle pathways linking
air pollution to adult-onset asthma with observed evidence of the
involvement of both linoleate metabolism and carnitine pathways
lending causal credibility to the association
-Transcriptional and microRNA changes observed after swimming were
linked to bladder and colon cancer risk from previous studies
(6) Is it possible to use the exposome approach to study the
life-course epidemiology of environmental diseases?
-Air pollution impacts on both asthma and cardiovascular disease via
pro-inflammatory and oxidative stress pathways, consistent with
accumulation of oxidative molecular damage over years of exposure
- Known candidate transcriptome profiles of blood pressure/insulin in
adulthood were associated with prenatal PM exposure at birth
-Longitudinal air pollution exposures were associated with alterations in
genes involved in neurotransmission and tumor suppression pathways
Abbreviations: DBP Disinfection by-product, LUR Land-use regression, NO2 Nitrogen dioxide, PM2.5 Particulate matter less than 2.5 μm in diameter, PEM Personal ex-
posure measurements, RR Relative risk, THM Trihalomethane, UFP Ultrafine particles
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through old age) to explore associations over the life-
course [4].
Air pollution
External Exposome
John Gulliver presented advances in monitoring of
personal exposures to air pollution in EXPOsOMICS.
Main goals of the project were to develop new land
use regression (LUR) models for ultrafine particles
(UFP) and oxidative potential, as well as undertake
personal measurements of particulate matter less than
2.5 μm in diameter (PM2.5) and UFP to investigate
the potential for exposure misclassification in using
outdoor models of exposure at the residential address
as the sole means of exposure assessment. Detailed
24 h PEM for particulate matter less than 2.5 μm in
diameter (PM2.5) and ultrafine particle (UFP)
estimates were conducted on approximately 200
participants with data on individual positioning and
accelerometry from smartphones in four European
countries. Findings contrasting personal UFP
exposures for individuals living near to traffic and in
background locations suggested that other microenvi-
ronments (journeys, work, home indoors etc.) are im-
portant contributors in determining levels of personal
UFP exposure. LUR models for PM2.5 and nitrogen
dioxide (NO2) concentrations in Western Europe were
developed for harmonised exposure assessment in epi-
demiological studies combining either satellite data
with local predictors (PM2.5) or chemical transport
modelling data with local predictors (NO2) [5]. New
outdoor spatial LUR models were also developed for
UFP in six European areas with good performance in
predicting 24 h outdoor home exposures [6] as well
as for oxidative potential of PM2.5 in five European
areas that provided an independent exposure metric
that was not strongly correlated with PM2.5 concen-
trations. Results provide insight into the contribution
of different microenvironments in air pollution expos-
ure and new exposure models for use in epidemio-
logical studies. Future efforts include the use of PEM
technology in larger study populations and epidemio-
logical studies.
Nicole Probst-Hensch presented the contribution of the
exposome approach towards understanding the associ-
ation of long-term PM2.5 exposure and asthma/cardiovas-
cular disease (CVD) in adults (see also below). Relative
risk (RR) estimates from the ESCAPE study for total
mortality, ischemic heart disease (IHD) incidence, and
asthma incidence [7, 8] were calibrated using low-end and
high-end deattenuation factors for PM2.5 exposure ob-
tained from the PEM study (above). Point risk estimates
were increased in comparison with non-calibrated esti-
mates based on LUR alone. Estimates of attributable
burden of IHD and asthma incidence due to PM2.5 expos-
ure in the EU-28 and Switzerland were also presented,
with an approximate 1.5 to 2-fold increase in disease bur-
den obtained using calibrated RR estimates from ESCAPE.
Results suggest that the contribution of PM2.5 to the
asthma and CVD burden may be underestimated using
existing methods.
Internal Exposome
Soterious Kyrtopoulos discussed the identification of
biomarkers of exposure in short-term experimental stud-
ies and of associated metabolic pathways potentially
linked with health risks. In initial results from the Ox-
ford Street study [9], a randomized cross-over study of
59 adults invited to walk for 2 h in both a high (Oxford
Street) and a low (Hyde Park) air pollution setting,
short-term exposure (2 h) to air pollutants induced
changes in omic profiles, especially gene expression and
metabolites which differed among the different air pol-
lutants with little overlap. In pathway/network analysis,
there was evidence of links with energy metabolism and
inflammation pathways, including the carnitine shuttle
pathway which was most significantly affected for NO2.
For most compounds, levels returned to pre-exposure
levels by 24 h. For transcriptomics, the greatest number
of signals was also related with NO2 exposure with little
overlap between pollutants which in pathway analysis
were related with the immune system and platelet aggre-
gation. Cross-omic analysis investigated overlap between
carnitine associated genes and transcriptomics markers.
Roel Vermeulen and Jelle Vlaanderen provided an
overview of the identification of omics markers of short-
term exposure to air pollution and the potential for
using PEM data to improve exposure estimates in larger,
long-term studies of air pollution. Although long-term
air pollution concentrations have been associated with
changes in omics markers, these studies are limited by
inconsistent findings across studies, crude exposure as-
sessment, and limited samples per individual [10–12].
The link with acute health effects is also often unclear.
Based on the PEMs of PM2.5 and UFP in four European
countries (see above), with three exposure and two
omics measurements per individual, positive associations
were observed between different immune markers and
personal PM2.5 and UFP concentrations. There were also
several CpG sites that were significantly associated with
personal PM2.5 concentrations. Findings based on re-
peated measurements provide knowledge around how
exposure and omics markers vary within individuals to
be able to better assess patterns in omics markers and
health outcomes between individuals. Further work to
contrast findings with those from studies of long-term
exposure is needed. Once omics signals strongly associ-
ated to specific air pollutants have been identified, these
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might provide an avenue for calibrating air pollution ex-
posure estimates in cohort studies via regression calibra-
tion techniques [13], potentially reflecting a more
biologically relevant exposure metric.
Nicole Probst-Hensch further presented the contribution
of the exposome approach towards understanding the
association between long-term exposure to air pollution
and asthma/CVD in adults (see also above). Results from
mediation analyses were consistent with air pollution
impacting on both asthma and CVD via pro-inflammatory
and oxidative stress pathways, albeit with different mole-
cules involved – consistent with accumulation of oxidative
molecular damage over years of exposure. Ayoung Jeong
used metabolomics to study meet-in-the-middle pathways
linking air pollution to adult-onset asthma in the SAPAL-
DIA and EPIC cohorts, with observed evidence of the in-
volvement of both linoleate metabolism and carnitine
pathways.
Lastly Tim Nawrot described multi-omic analyses to
identify signals associated with in utero exposures to air
pollution (particulate matter less than 10 μm in diameter
(PM10) and PM2.5) and early life effects in five European
birth cohorts. Transcriptome wide microarray analysis
was undertaken to understand biological and develop-
mental origins of health and disease mechanisms related
with blood pressure and insulin; epigenome-wide ana-
lysis to study longitudinal signals associated with early
life exposure; and metabolome-wide analysis of cord
blood to investigate metabolic signatures of birthweight
and the influence of PM exposure. Known candidate
transcriptome profiles of blood pressure/insulin in adult-
hood [14] were associated with prenatal PM exposure at
birth with different responses observed in boys and girls.
The top significant newborn PM transcripts observed
have functional consequences based on associations with
cord metabolites and protein targets. Longitudinal air
pollution exposures were associated with alterations in
genes involved in neurotransmission and tumor suppres-
sion pathways. Further work to examine consistency in
findings across studies and across omics platforms is
needed.
Water contamination
External Exposome
Manolis Kogevinas presented work that focused on
chemical contaminants in water produced during the
process of disinfection. Hundreds of disinfection by-
products (DBPs) are produced when disinfecting water
usually through chlorination [15]. Some of them are
animal carcinogens, several are mutagens or have shown
genotoxicity in a variety of assays, and epidemiological
studies have associated exposure to trihalomethanes (the
most common DBPs) with bladder cancer [16]. There is
only limited evidence on the association with colorectal
cancer in humans [17]. In EXPOsOMICS, a short-term
study (PISCINA2) measured an expanded range of DBPs
(trihalomethanes, haloacetic acids, MX, chloramines,
haloacetonitriles) in air, water and/or in biological sam-
ples such as exhaled breath (e.g. trihalomethanes) and
urine (haloacetic acids) from study subjects, overcoming
traditional approaches that measure only trihalometh-
anes [18]. In mother-child cohorts, external exposure
measurement included determinations of a range of
DBP chemicals in drinking water (trihalomethanes
(THM), haloacetic acids, haloacetonitrile), with some
available from the EU-funded HiWate project [18]. In
the colorectal cancer study (MCC-Spain), exposure
modeling of DBPs was based on the evaluation of life-
time residential history together with the collection of
historical information on DBPs in the relevant regions
and water toxicity testing from short-term studies. Re-
sults did not show an overall association of colorectal
cancer with THM exposure [17]. An increase in risk was
observed only for subjects exposed to high levels of
brominated THM concentrations; experimental evidence
indicates that brominated compounds are more toxic
than chlorinated compounds [19, 20]. Finally, although
THMs are regulated in the EU there are no central sta-
tistics available on THM exposure in EU countries. As
part of the burden of disease component of EXPOsO-
MICS, regulatory or other agencies in all EU countries
were contacted and a map with average current THM
levels in the 28 EU countries was produced for the first
time. The map showed considerable differences between
countries with very low levels observed in countries such
as Denmark and The Netherlands and high levels ob-
served in countries such as Spain, Romania and Ireland.
A burden of disease estimation indicated that more than
6000 bladder cancer cases can be attributed to THM
exposure in the EU each year.
Internal Exposome
Part of the controversy concerning potential health ef-
fects from exposure to chemical contaminants produced
during disinfection i.e. chloroform or bromoform, is due
to the fairly low toxicity of these chemicals at the con-
centrations usually observed in drinking water [20].
Manolis Kogevinas presented work conducted in EXPO-
sOMICS in a semi-experimental study (PISCINA2) in
swimmers in an indoor pool evaluating short term ef-
fects and in a population-based study evaluating long-
term exposures and showed that numerous hits were
identified when contrasting pre- and post-swimming
omic profiles. Transcriptomics, targeted proteomics and
metabolomics were examined in the swimming pool
study together with an evaluation of genotoxicity bio-
markers (micronuclei) and markers of lung epithelium
permeability (club cell protein – CC16). The study on
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proteomics indicated that swimming in a chlorinated
pool induces perturbations of the immune response
through acute alterations of patterns of cytokine and
chemokine secretion [21]. The transcriptomics analysis
identified more than 1700 genes and several microRNAs
that were significantly associated with exposure to at
least one DBP. Among transcripts that had not been
previously reported to be associated with physical acti-
vity, a large number of hits remained associated with
DBP exposure and several of those are linked with blad-
der and colon cancer. Numerous molecular changes
were identified in the metabolomic analysis following
the swimming experiment and related to exposure
changes. No clear associations were observed for the
genotoxicity biomarkers and this contrasted with an
earlier swimming pool study that was conducted among
swimmers with very high levels of brominated
compounds [22]. Results for metabolomics, proteomics
and methylation following long-term exposure in the
MCC-Spain study were also presented. Numerous hits
were identified although overall findings were less prom-
inent than those observed in the short-term swimming
pool study. Some proteomic markers (mainly interleu-
kins) were detected in association with long-term THM
exposure from the MCC study controls.
Methods
New Technologies for Environmental Health Research –
Adductomics
David Phillips presented “New technologies for environ-
mental health research – adductomics”. Adductomics, the
untargeted detection of DNA or protein adducts of en-
dogenous or exogenous origin, is a new field in exposome
research. Many of the studies in this area focus on the
untargeted analysis of protein adducts in human serum al-
bumin (Cys34 - the major site of modification) through a
method developed in 2011 [23] that has been adapted for
higher-throughput use in EXPOsOMICS adductomics
studies [24]. The half-life of albumin (20–25 days) means
that measurements of its covalent adducts reflect a longer
“capture period” of exposure than other more transient
omics biomarkers. The majority of studies to date have
been concerned with quality control and methodological
development and validation, but the first analyses in some
of the EXPOsOMICS studies (PISCINA2, PEM, Oxford
Street) and other epidemiological studies (i.e. EPIC) are
starting to yield promising results with the identification
of correlations between specific adducts and different
environmental exposures or disease states. Further
methodological developments are still required, including
the development of new analytical methods and the cre-
ation of adduct libraries for annotation, but adductomics
is set to become another key component in the study of
the exposome.
Statistics in Exposome Research
Marc Chadeau-Hyam and Roel Vermeulen presented
“Statistics in Exposome Research: from omics profiling to
dynamic modelling”. The presentation outlined some of
the main challenges in the analysis of large, complex
datasets produced by untargeted omics analyses in studies
of the exposome (i.e. simultaneous testing of multiple hy-
potheses, consideration of multiple correlated exposures,
of exposure interactions and non-linear exposure-
response relations, and of temporal factors in exposures)
together with the statistical tools being developed to
address them [25]. Examples of the application of estab-
lished statistical methods to analyses of data from EXPO-
sOMICS and HELIX studies were presented, including: a
comparison of several multivariate regression-based
methods for identifying true exposure-outcome associa-
tions from a large set of correlated exposures [26]; the use
of techniques for analysing multivariate data, such as
multi-level partial least squares (PLS) methods, in the ana-
lysis of data from the PISCINA2 study, for identifying spe-
cific molecular signatures representative of disinfection
by-product exposure; the use of network representation
methods for the identification of key signals or combina-
tions of signals in omics data that play a pivotal role in
describing the association between exposure and effect,
illustrated by analyses of transcriptomic profiles in the
PISCINA2 study and of epigenome-wide association
studies of smoking and lung cancer risk [27]. Finally, the
dissemination and training activities in statistical analysis
of omics data integrated in the EXPOsOMICS and HELIX
projects were also presented.
Plenary discussion – External Exposome
The plenary session on the “External Exposome” led by
Roel Vermeulen and Gary Miller discussed the following
questions:
 What can be the contribution of exposure science to
hazard identification and risk assessment?
 What is the state of the art of new exposure
measurement technologies?
 What are the research needs?
The development of mobile technologies and of smaller,
cheaper sensors allows for easier and more frequent
collection of data on exposures in research participants
(i.e. location, air pollutants, noise, diet) and the modelling
of exposures in the wider population to numerous envir-
onmental factors [28]. Commercial personal monitoring
devices will continue to get cheaper and more accurate
and in a few years will likely be accurate enough for re-
search purposes. There is also the potential for crowd-
sourcing data and the use of data from commercial
providers, including social media, to capture a range of
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exposure data, including on the wider social-ecological
context [29]. With better understanding of the correl-
ation structure of many exposures, i.e. through correl-
ation globes, we may in due time be able to construct
Exposome Maps with smaller numbers of exposures be-
ing representative of a broader exposure profile (akin to
HapMap) [30, 31].
There remain however a number of methodological
challenges to document the external exposome
(Table 2). There are currently many poor quality
sensors on the market and a need for thorough valid-
ation of new and existing sensors. It would be useful
to provide information on the quality of available de-
vices such as the U.S. Environmental Protection
Agency air sensors toolbox (www.epa.gov/air-sensor-
toolbox) that provides general guidance to the public,
researchers, and developers on available air pollution
monitoring devices. It would also be useful to
compare information obtained using different mobile
applications such as those developed specifically for
research purposes vs. commercially available apps (i.e.
ExpoApp developed for the European CITI-SENSE
project (http://www.citi-sense.eu/) [32] vs. commer-
cially available Moves (https://moves-app.com/)).
Although photo-based methods and wearable cameras
have been implemented in epidemiological studies to
better understand participant diet, location, or time-
activity behavior patterns, further work is needed in
the processing of such data. For example, in the case
of dietary assessment to go beyond estimating food
volume to recognising specific types of food or
cooking method [33]. There is a need to define the
optimal vs. sufficient level of resolution required for
research and policy-making as well as participant ad-
herence and measurement in large-scale populations.
There are also outstanding questions regarding who
will collect and store data as well as have access and
ownership [28].
Plenary discussion – Internal Exposome
The plenary session on the “Internal Exposome” led by
Paolo Vineis and Tim Gant discussed the following
questions:
 What can be the contribution of omic
measurements in hazard identification and risk
assessment?
 What are the current limitations?
 What are the most urgent needs in the field of
omics research?
At present omics approaches are useful in biomarker
discovery and research, also for hypothesis generation,
but it will take time to validate omics approaches to the
point that there is sufficient confidence for use in regula-
tory and policy decisions. There are both agnostic and
targeted approaches with different advantages (hypoth-
esis generation vs. refining knowledge on mechanisms)
and the opportunity for cross-validation and discovery
of new biomarkers/mechanisms by combining both ap-
proaches. Omics data may also be useful to inform
physiologically-based pharmacokinetic modelling (PBPK)
to improve internal exposure estimates integrating
epidemiology and toxicology approaches or as a tool to
develop more cost effective interventions by focusing on
the most relevant pathways/networks for prevention.
Limitations of omics are different depending on
intended use, i.e. quantifying exposures or downstream
markers of pathways associated with disease outcomes
(Table 2). There is also a limited understanding of
biological pathways, particularly interactions between
different pathways. Although omics have contributed to
Table 2 Key scientific and policy challenges identified as part of the EXPOsOMICS project.
Type of Challenge Challenge
Scientific -Availability of accurate and inexpensive sensors
-Low statistical power (low levels of exposure and small omic changes)
-Multi-city designs are needed for contrast, but complicate inference
-Validation in larger, longer-term exposed populations and in different settings and across omics platforms
-Collection and storage of data as well as data access and ownership
-Limited understanding of biological pathways and their interaction
-Limited capacity to look at historical exposures
-Large variation in bioinformatics analyses
-Validation of omics approaches (both technical validation and biological validation) and a lack of a platform for data sharing
-Matching omics measurements with functionalities (annotation of unknown biomarkers, differentiating exposures from
biological responses, investigation of mixtures and interactions between agents)
-Understanding mechanisms for biological plausibility and causality assessment
-Cost of omics
Policy -Current regulatory standards and policy not yet adapted to the use of EXPOsOMICS evidence
-Conceptual framework for integrating the contribution of exposome or external exposure data into models of disease
-Communication of research results
-Demonstrate the utility of the exposome approach to funders and policy makers
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advancing the field, i.e. use of overlaps across different
omics to identify the most robust findings, there is a
need to recognise the danger of over-interpreting results.
There is a limited capacity to look at historical exposures
- adductomics may provide longer-term information
compared to other omics, but this still requires
validation. There is difficulty in distinguishing effects of
exposures from the effects of disease processes associ-
ated with them in analyses of the internal exposome.
There is also a large variation in bioinformatics analyses
of omics data and consequently a need for increased
standardization and reproducibility. There is a need for
validation of omics approaches (both technical validation
and biological validation) and a lack of a platform for
data sharing. A recommendation is to develop an inter-
national initiative to promote data sharing and setting of
standards for the reporting and validation of omics
markers. Finally, although the cost of omics analysis is
decreasing, it remains a limiting factor in most studies.
Plenary discussion: Policy translation
The plenary session on “Policy translation” led by David
Balshaw and Christopher Wild discussed the following
questions:
 In the light of the philosophy expressed in the U.S.
National Academy of Sciences (NAS) report on
pathway perturbation, what is the potential
contribution of the exposome paradigm?
 How does it fit into the strategies of environmental
and public health agencies, NGOs, regulatory
agencies, industry and academia? What institutional
actors are necessary?
 How should research be funded to meet the next
challenges of exposome research?
Before discussing the potential contribution of the
exposome to policy development it was important to
consider what is meant by policy: guidance, recommen-
dations and legislation each has different requirement
levels for evidence. It is also important to bear in mind
the many factors that affect the translation of science
into policy including public and media pressure,
economic interests, and political agendas, for example.
On a basic level, exposome research can be seen as
replicating the approaches of classic risk assessment with
higher resolution and greater accuracy. This includes
improved exposure assessment with the ability to cap-
ture correlated co-exposures, complex mixtures, and
synergies, the provision of dose-response data including
at low-dose exposures, and biological plausibility of
exposure-disease associations by bridging experimental
and human data (for example by identifying the same
epigenetic or metabolomic signatures in both animal
and human studies). Identifying susceptible sub-groups
and critical windows of exposure, monitoring prevalence
and level of exposure and evaluating interventions
through short-term endpoints and/or mechanism-based
markers can also be performed.
However, pathway perturbation (a more general concept
than the adverse outcome pathway (AOP)) is a change of
paradigm, a new way of thinking about hazard identifica-
tion and risk assessment by using pathway analysis to link
multifactorial causality with risk decisions [34]. Exposome
research can provide essential information on early
perturbation of pathways at low levels of exposure, as this
project shows in relation to air pollution and water con-
taminants. The possibility of evaluating complex mixtures
and synergies between compounds is also a change of
paradigm from evaluating risk for individual agents. Our
understanding of the dynamic changes and interactions in
pathways and the way they relate to exposures are still
patchy; this limits the way pathway analysis can be used to
identify multifactorial aetiology underlying disease, at least
at present. Further, current regulatory standards and
policy currently focus on animal models for mechanistic
evidence and biological plausibility and epidemiological
evidence for strength of association as pre-requisites (i.e.
Bradford-Hill causality assessment criteria [35]) which are
also not yet adapted to the use of EXPOsOMICS evidence
(pathway analysis/pathway perturbation) for risk
assessment.
There is an opportunity for EXPOsOMICS to contri-
bute to breaking the institutional silos in policy-making
organisations, by promoting integrated approaches that
examine the effects of multiple categories of agents in a
more holistic approach to risk assessment [36]. However,
policy development is typically slow due to powerful
pressures from existing interests; this will condition the
speed with which novel approaches and data from
EXPOsOMICS will be accepted for translation into
policy. In the face of resistance from vested interests,
translating evidence into policy requires strong, well
organised commitment; including the consideration of
engaging with other groups in society with an interest in
the protection of public health and the environment
either as a direct or co-benefit.
Considerations for exposome research to better link
with policy-making were also discussed including noting
the big gap in the way questions are framed in a
scientific vs. a regulatory/policy context and a need to
consider from the stage of design how study results can
be relevant to and presented in a way that can be
integrated into regulatory/decision-making processes
(Table 2). Improved dialogue with policy-makers is
needed to better understand research needs for policy-
making and in the translation of EXPOsOMICS findings
into understandable messaging.
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Complementarities with other initiatives
Helix
Martine Vrijheid presented an overview of the progress
of the HELIX project [37] www.projecthelix.eu and com-
plementarities with EXPOsOMICS. HELIX provides a
wide coverage of the exposome during the early-life, in-
cluding a range of 200–300 individual and chemical (i.e.
polychlorinated biphenyls, phthalates, metals, social fac-
tors), outdoor urban (i.e. air pollutants, noise, built en-
vironment/green spaces), and internal environments (i.e.
metabolomics, proteomics, transcriptomics, DNA
methylation), based in six existing European birth
cohorts. The main progress relates to describing the
exposome and its determinants across Europe in
mothers and their children, including correlations
between exposures [31]; characterizing personal expo-
somes and short- and long-term variability both within
and between participants; determining omics signatures
related to multiple early life environmental exposures;
and relating the exposome to child health. HELIX con-
tributes comparable biomonitoring, geospatial, and
omics data in several European countries which can be
used to identify high-risk groups and provide a holistic
picture on important sources and determinants of mul-
tiple environmental exposures. It provides a toolkit for
personal exposome assessment including various
personal-level sensors, an in-depth characterisation of
temporal variability in exposures through repeated
sampling, and molecular fingerprints within and be-
tween individuals [38]. Investigation of omics signatures
and molecular pathways in vulnerable time periods can
be used for improved risk assessment and prediction of
future disease risk as well as better understanding of
biological mechanisms when combined with pathway
analysis. Finally, systematic evaluation of child health ef-
fects of multiple exposures allows for the identification
and prioritization of important environmental exposures,
and the estimation of their associated health impact to
ultimately lead to improved prevention strategies.
NIH/NIEHS
David Balshaw outlined “Exposome initiatives at NIH/
NIEHS” including current approaches in exposome
research in light of the recent U.S. NAS report [34],
and the parallels to the EXPOsOMICS and HELIX
programmes. The exposome concept provides a
framework for moving environmental health research
from a reductionist approach – one exposure, one
disease – to considering the influence of multiple
stressors at multiple time-points. Research on the
exposome is moving from concept to the demonstra-
tion stage – starting to show with the limited tools
available at present some of the potential of this ap-
proach, but requiring in parallel the development of
capacity to look at multiple exposures through the
development of better technical and methodological
tools and validation in real-world conditions. The
Children’s Health Exposure Analysis Resource
(CHEAR) study was presented as a demonstration
case for exposome research at NIEHS, comprising
two main components, research and development of
infrastructure. The early stages have focused on de-
velopment of standards and quality assurance to im-
prove reproducibility of the analyses, and the creation
of a data repository for health histories and omics
data. The potential for cross-validation between tar-
geted (hypothesis-driven) and untargeted (agnostic)
approaches and the use of additional data on bio-
logical responses to anchor targeted and untargeted
analyses are being evaluated. Future perspectives in-
clude exploring the contribution of the exposome and
multi-omic integration for mechanistic research and
systems biology. Some of the key immediate chal-
lenges in exposome research include: compound iden-
tification from untargeted analyses; making data
accessible for further analyses; and using the expo-
some concept as a tool for prevention.
US NAS Twenty-First Century Risk Assessment
Jonathan Samet presented the report “Using 21st
Century Science to Improve Risk-Related Evaluations”
developed by a committee convened in 2016 by the U.S.
NAS [34]. The report builds on earlier initiatives in the
U.S. (“Toxicity testing in the 21st Century” in 2007 [39]
and “Exposure Science in the 21st Century” in 2012 [40])
and internationally (REACH programme in Europe), to
guide the development of new scientific and technical
methodologies for exposure monitoring, toxicological
evaluation, epidemiology, and their application to risk
assessment. Advances in exposure science, with the in-
creasing use of more sophisticated exposure monitors
and the use of omics technologies to investigate bio-
logical responses, present new opportunities for example
for the analysis of multiple exposures and of pathways
linking exposures and outcomes, however they also
present challenges in the analysis, integration and
interpretation of large volumes of diverse data, and on
linking these to potential risks for human health. The
concepts of “pathway perturbation” and “meet-in-the-
middle”, i.e. identifying biomarkers linking exposures
and disease outcomes, were identified by the NAS
committee as central to these new approaches for risk
assessment. Finally, the criteria traditionally used for
causal assessment, such as the Bradford-Hill criteria
(also above), will need to be developed and adapted to
integrate these new approaches, and for the moment
guided expert judgement should be used for integrating
the diverse data streams to draw causal conclusions.
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The future of the Exposome
The New Science of Exposure Assessment
Mark Nieuwenhuijsen, in a presentation “The new
science of exposure assessment”, highlighted new de-
velopments in assessments of the outdoor exposome,
including in environmental measurements and mod-
elling, and remote and personal sensing. Challenges
in this area include: improving resolution of remote
sensing and the accuracy and miniaturisation of per-
sonal sensing devices [32]; increasing accessibility of
environmental data through the creation of data re-
positories; and integrating different sources of infor-
mation, i.e. remote sensing, ambient monitoring,
modelling and personal monitoring [41]. The re-
marks by Gary Miller as the discussant, and the dis-
cussion that followed, emphasised the importance of
the complementarity of the approaches provided by
the external and internal exposome studies, not just
by increasing confidence in matching observations,
but also by making the direct link between pathway
perturbations observed in studies of the internal
exposome, with external factors that can then be
identified as priorities for preventive interventions
and policy making. The speed of technological devel-
opments in this area presents good opportunities but
limited funding continues to be a major challenge
and delays further significant advances.
Weak Carcinogens and “Pathway Perturbation”
Paolo Vineis in a presentation “Weak carcinogens
and “pathway perturbation””, highlighted some of the
ways in which EXPOsOMICS research is contribu-
ting to assessments of carcinogenicity, including:
contributing mechanistic data to biological plausibil-
ity assessments; contributing to the refinement of
models of carcinogenesis (hallmarks of carcinogen-
esis [42, 43]), although still missing is a conceptual
framework for integrating the contribution of expo-
some or external exposure data into these models;
contributions to improved measurements and
identification of omics alterations at low doses; in
conjunction with epidemiological studies contribut-
ing additional data to causality assessment for weak
carcinogens. Tim Gant, as a discussant, emphasised
the different perspectives from epidemiology and
toxicology on carcinogen identification, and
highlighted some of the gaps in our current under-
standing of the downstream effects of observed path-
way changes, including: difficulty in distinguishing
between transient changes in response to a short-
term stressor (homeostasis) and long-term changes
in response to a chronic exposure; difficulty in
distinguishing between pathway changes that lead to
an adverse effect vs. those that lead to metabolic
adaptation to a low-dose exposure (hormesis). There
is a difficulty in funding work on developing the
technical resolution to address these gaps in know-
ledge, but it is increasingly needed. In the discussion
that followed the use of the term “weak carcinogens”
was challenged: the meaning is difficult to define
(weak association? weak evidence?) and problematic
as it is open to misinterpretation in policy settings
as being unimportant and so easily dismissed.
New Developments of the Exposome Concept
Lastly, Christopher Wild presented on “New develop-
ments of the “Exposome” concept”. The presentation
highlighted the remarkable progress in exposomics
research in a short period of time [44–48]. Being an
emerging discipline, our understanding still necessarily
has gaps but we should not be discouraged by these
limitations as long as we recognise limitations in the in-
terpretation of the data. Major challenges for exposome
research remain: validating exposure measurements
(reliability of individual measures) [49], data integration
and analysis (understanding correlations of exposures
and the role of confounders) [47], matching omics mea-
surements with functionalities (annotation of unknown
biomarkers; differentiating exposures from biological
responses; investigation of mixtures and interactions
between agents; understanding mechanisms for biological
plausibility and causality assessment). It is important to re-
main focused on the key questions – characterizing
exposure-disease relationships – and to invest further in
method development and validation. The discussant
Marco Martuzzi, emphasised the importance and rele-
vance of research on the exposome in the context of the
development of interventions targeted at the population
level to improve public health [50, 51]. In contrast, the ap-
plication of the genome lies in interventions targeted to
individuals. The need to develop criteria for defining en-
vironmental health priorities to guide priority setting and
investment in research informing policy development was
also highlighted.
Conclusion
The meeting concluded with feedback on the EXPO-
sOMICS project from the European Commission and
the International Scientific Advisory Board. Overall,
EXPOsOMICS provides proof-of-principle that an
exposome approach can lead to important findings
that have an impact both on knowledge of the
mechanisms linking exposure to common pollutants
with diseases, and on preventive and regulatory ac-
tion. The potential of exposome research to contrib-
ute to policy development includes: improved
exposure assessment; enhanced specificity of actions
to remove environmental hazards; identification of
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subgroups at risk; enhanced prediction and preven-
tion of disease by early intervention; monitoring of
results of policies in reducing exposures; and eluci-
dation of new hypotheses on the role of environment
and health. Current limitations of this area were dis-
cussed in terms of showing added value for public
health including the need to: improve communica-
tion of research results to non-scientific audiences
and promote interaction among the producers and
users of research; target research to the broader
landscape of societal challenges – i.e. target priority
policy areas that are under-researched or where
current methods do not provide appropriate answers;
and become better at drawing applicable conclusions
– i.e. what is the added value of the research and
what is the follow-up. Priorities for future work
include the development and standardization of
methodologies and technologies for assessing the ex-
ternal and internal exposome, improved data sharing
and integration, and the demonstration of the added
value of exposome science over conventional
approaches in answering priority policy questions.
Being a new field, there will be a need to continue
to demonstrate the utility of the exposome approach
to funders and policy makers.
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